More research into CNTF treatment required

Article

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

According to a study published in Investigative Ophthalmology and Visual Science more research into the effect of sustained-release ciliary neurotrophic factor (CNTF) treatment, on patients with inherited retinal degenerations, using high-resolution imaging techniques is required.

Dr Jacque L. Duncan from the Beckman Vision Center, School of Medicine, University of California, San Francisco, California, USA, led a study group in the examination of the cone photoreceptor structure and function of the 2 patients with retinitis pigmentosa and 1 patient with usher syndrome.

All patients participated in a phase II clinical trial and were treated with sustained-release CNTF delivered by an encapsulated cell technology implant in one eye and sham surgery in the other. The outcome measures were obtained using AOSLO.

The results show that outer retinal layers were significantly thicker in CNTF treated eyes than the sham-treated eyes. The findings demonstrated there were no significant changes in VA, visual field sensitivity or ERG responses. AOSLO is a sensitive way to measure disease progression and reactions to treatment in patients. A larger study is required to determine the effect of CNTF treatment in inherited retinal degenerations.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.